Anthropic IPO filing reveals plans to build a drug discovery lab and pursue AI-driven therapeutics, noting scientific and regulatory hurdles

Anthropic, known for its Claude AI platform, disclosed in its S-1 that it intends to expand into life-science research, including establishing its own molecular biology laboratory.

The company aims to use advanced AI models, termed "Powerful AI," to accelerate drug discovery, disease detection and the development of personalized therapies.

Anthropic cautioned that entering drug development brings significant scientific, regulatory and operational challenges that differ from its core software business.

The filing emphasizes that while AI could eventually generate drug candidates, the firm acknowledges the associated risks and the need for responsible management.